Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants
March 29 2022 - 4:01PM
Business Wire
Geron Corporation (Nasdaq: GERN), a late-stage clinical
biopharmaceutical company, today announced that it intends to offer
and sell shares of its common stock, or for certain investors that
so choose, in lieu of shares of its common stock, pre-funded
warrants to purchase shares of its common stock, together with
accompanying warrants to purchase shares of its common stock in an
underwritten public offering. All of the securities in the proposed
offering are to be sold by Geron. The offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or
terms of the offering.
Stifel and Baird are acting as joint book-running managers for
the proposed offering. Needham & Company is acting as lead
manager for the proposed offering.
A shelf registration statement on Form S-3 relating to the
public offering of the shares of common stock, pre-funded warrants
and accompanying warrants described above was previously filed with
the Securities and Exchange Commission (SEC) and subsequently
declared effective by the SEC. A preliminary prospectus supplement
relating to and describing the terms of the proposed offering will
be filed with the SEC and will be available on the SEC’s web site
at www.sec.gov. When available, copies of the preliminary
prospectus supplement relating to the proposed offering may also be
obtained from Stifel, Nicolaus & Company, Incorporated,
Attention: Syndicate, One Montgomery Street, Suite 3700, San
Francisco, California 94104, by telephone at 415-364-2720 or by
email at syndprospectus@stifel.com or Robert W. Baird & Co.
Incorporated, Attention: Syndicate Department, 777 East Wisconsin
Avenue, Milwaukee, Wisconsin 53202, by telephone at 800-792-2473 or
by email at syndicate@rwbaird.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of these securities, nor will
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Geron
Geron is a late-stage clinical biopharmaceutical company focused
on the development and potential commercialization of a
first-in-class telomerase inhibitor, imetelstat, in hematologic
malignancies. The Company currently is conducting two Phase 3
clinical trials: IMerge in lower risk myelodysplastic syndromes and
IMpactMF in refractory myelofibrosis.
Use of Forward-Looking Statements
Investors are cautioned that statements in this press release
regarding the intention, completion, timing and option relating to
the proposed public offering constitute forward-looking statements
that involve risks and uncertainties, including, without
limitation, risks and uncertainties related to: whether or not
Geron will be able to raise capital through the sale of its
securities; the final terms of the proposed offering, market and
other conditions; the satisfaction of customary closing conditions
related to the proposed public offering and the impact of general
economic, industry or political conditions in the United States or
internationally, including the impact of the COVID-19 pandemic
and/or the Russia/Ukraine conflict on Geron’s business operations
and activities. There can be no assurance that Geron will be able
to complete the proposed public offering on acceptable terms, or at
all. Geron will continue to need significant additional capital to
fund its operations and may be unable to raise capital when needed,
which would force Geron to delay, reduce or eliminate its
imetelstat development program. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on other potential factors that
could affect Geron’s results and other risks and uncertainties can
be found under the heading “Risk Factors” in Geron’s periodic
reports, including its annual report on Form 10-K for the year
ended December 31, 2021 and in the preliminary prospectus
supplement related to the proposed offering to be filed with the
SEC on or about the date hereof, each available on the SEC’s web
site at www.sec.gov. Geron expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220329005963/en/
Aron Feingold Investor and Media Relations investor@geron.com
media@geron.com
Geron (NASDAQ:GERN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From Apr 2023 to Apr 2024